54234-59-2

Usage

Uses

Used in Organic Synthesis:
(3,4-dihydroxyphenyl)acetyl chloride is used as a reagent for introducing the acetyl group into various organic molecules. Its reactivity allows for the formation of new chemical bonds and the synthesis of a wide range of organic compounds.
Used in Pharmaceutical Production:
(3,4-dihydroxyphenyl)acetyl chloride is used as an intermediate in the production of pharmaceuticals. Its ability to acylate other molecules makes it a valuable component in the synthesis of various drug compounds.
Used in Agrochemical Production:
(3,4-dihydroxyphenyl)acetyl chloride is also used in the production of agrochemicals. Its reactivity and ability to form new chemical bonds contribute to the development of effective agricultural products.
Used in Research and Development:
Due to its reactivity and unique chemical properties, (3,4-dihydroxyphenyl)acetyl chloride is used in research and development for the discovery and optimization of new chemical compounds and processes.
Safety Precautions:
(3,4-dihydroxyphenyl)acetyl chloride is highly reactive and should be handled with caution. It has the potential to cause skin and respiratory irritations, and appropriate safety measures should be taken when working with (3,4-dihydroxyphenyl)acetyl chloride.

InChI:InChI=1/C8H7ClO3/c9-8(12)4-5-1-2-6(10)7(11)3-5/h1-3,10-11H,4H2

Upstream product

• 102-32-9 3,4-dihydroxyphenylacetate 

Downstream Products

• 1243290-18-7 N-(1-(1H-benzo[d][1,2,3]triazol-1-yl)-2,2-dimethylpropyl)-2-(3,4-dihydroxyphenyl)acetamide 
• 1129-53-9 3,4-dihydroxyphenylacetamide 

Relevant academic research and scientific papers

Small Molecule Inhibitors of the BfrB-Bfd Interaction Decrease Pseudomonas aeruginosa Fitness and Potentiate Fluoroquinolone Activity

The iron storage protein bacterioferritin (BfrB) is central to bacterial iron homeostasis. The mobilization of iron from BfrB, which requires binding by a cognate ferredoxin (Bfd), is essential to the regulation of cytosolic iron levels in P. aeruginosa. This paper describes the structure-guided development of small molecule inhibitors of the BfrB-Bfd protein-protein interaction. The process was initiated by screening a fragment library and followed by obtaining the structure of a fragment hit bound to BfrB. The structural insights were used to develop a series of 4-(benzylamino)- A nd 4-((3-phenylpropyl)amino)-isoindoline-1,3-dione analogs that selectively bind BfrB at the Bfd binding site. Challenging P. aeruginosa cells with the 4-substituted isoindoline analogs revealed a dose-dependent growth phenotype. Further investigation determined that the analogs elicit a pyoverdin hyperproduction phenotype that is consistent with blockade of the BfrB-Bfd interaction and ensuing irreversible accumulation of iron in BfrB, with concomitant depletion of iron in the cytosol. The irreversible accumulation of iron in BfrB prompted by the 4-substituted isoindoline analogs was confirmed by visualization of BfrB-iron in P. aeruginosa cell lysates separated on native PAGE gels and stained for iron with Ferene S. Challenging P. aeruginosa cultures with a combination of commercial fluoroquinolone and our isoindoline analogs results in significantly lower cell survival relative to treatment with either antibiotic or analog alone. Collectively, these findings furnish proof of concept for the usefulness of small molecule probes designed to dysregulate bacterial iron homeostasis by targeting a protein-protein interaction pivotal for iron storage in the bacterial cell.

N-monoarylacetothioureas as potent urease inhibitors: synthesis, SAR, and biological evaluation

A urease inhibitor with good in vivo profile is considered as an alternative agent for treating infections caused by urease-producing bacteria such as Helicobacter pylori. Here, we report a series of N-monosubstituted thioureas, which act as effective urease inhibitors with very low cytotoxicity. One compound (b19) was evaluated in detail and shows promising features for further development as an agent to treat H. pylori caused diseases. Excellent values for the inhibition of b19 against both extracted urease and urease in intact cell were observed, which shows IC50 values of 0.16 ± 0.05 and 3.86 ± 0.10 μM, being 170- and 44-fold more potent than the clinically used drug AHA, respectively. Docking simulations suggested that the monosubstituted thiourea moiety penetrates urea binding site. In addition, b19 is a rapid and reversible urease inhibitor, and displays nM affinity to urease with very slow dissociation (koff=1.60 × 10?3 s?1) from the catalytic domain.

Synthesis, characterization and cardioprotective activity of some novel benzotriazole and pyrazole derivatives

A series of N-(1-(1H-benzo[d]) [1,2,3]triazol-1-yl)-2,2-dimethyl propyl)-2-(substituted phenyl) acetamide derivatives and methyl 5-((4- (2,5-disubstituted phenyl) furan-2 carboxylate derivatives are prepared from different substituted aryl carboxylic acids, phenyl acetic acid and cinnamic acid, respectively. All the synthesized compounds are investigated for cardioprotective activity by ischemia reperfusion method, while all the compounds show significant activity.

Specific bradycardic agents. 1. Chemistry, pharmacology, and structure-activity relationships of substituted benzazepinones, a new class of compounds exerting antiischemic properties

Structural modification of the calcium-antagonist verapamil (1) by replacement of the lipophilic α-isopropylacetonitrile moiety by various heterocyclic ring systems has led to a new class of cardiovascular compounds which are characterized by a specific bradycardic activity. These agents reduce heart rate without binding to classical calcium channels or β-adrenoceptors, interacting instead specifically with structures at the sino atrial node. Therefore they have also been termed sinus node inhibition. The prototype falipamil (2) has been submitted to furthr optimization mainly hy manipulation of the phthalimidine moiety. This has resultd in a secod generation of specific bradycardic agents with increased potency and selectively and prolonged duration of action represented by the benzazepinone-derivative UL-FS 49 (4). Structure-activity relationships within this novel class of compounds have revealed a marked dependence of activity on the substitution pattern of the aromatic rings, the nature of the central nitrogen atom, and the length of the connecting alkyl chains. The crucial role of the benzazepione ring for bradycardic activity can be best explained by its special impact on the overall molecular conformation.